Journal
BREAST
Volume 43, Issue -, Pages 130-134Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2018.12.001
Keywords
Breast cancer; Epigenetic; Histone acetylation
Categories
Funding
- European School of Oncology
Ask authors/readers for more resources
Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available